跳至主要内容
临床试验/NCT07349277
NCT07349277招募中不适用

Evaluation of sFlt-1/PlGF Ratio, Osteoprotegerin (OPG) and Soluble Endoglin (sEng) as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia

Ammar Jassim Abed1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2025年10月10日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
120
试验地点
1
主要终点
Change in sFlt-1/PlGF ratio and soluble endoglin (sEng) levels in preeclamptic patients compared to healthy pregnant controls.

研究概览

简要总结

his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide

详细描述

Preeclampsia is a pregnancy-specific hypertensive disorder characterized by newonset hypertension and proteinuria or other maternal organ dysfunction after 20 weeks of gestation. It affects 2-8% of pregnancies globally and remains a major contributor to maternal and perinatal morbidity and mortality The etiology is multifactorial, but placental dysfunction and abnormal angiogenesis are central to its pathogenesis. Given the limitations of current clinical indicators (e.g., blood pressure, proteinuria), there is growing interest in identifying predictive and diagnostic biomarkers to improve early detection, prognosis, and monitoring of therapeutic response. This study proposes to investigate three biomarkers: the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG), based on their roles in angiogenesis and endothelial dysfunction, which are hallmarks of preeclampsia

sFlt-1/PlGF Ratio Soluble fms-like tyrosine kinase-1 (sFlt-1) is an anti-angiogenic protein that binds to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with endothelial receptors. The imbalance, especially elevated sFlt-1 and decreased PlGF, is characteristic of preeclampsia. Numerous studies, including the multicenter PROGNOSIS trial, have validated the sFlt-1/PlGF ratio as a strong predictor of preeclampsia. A ratio ≥85 is associated with a high risk of developing preeclampsia within two weeks, while ≤38 effectively rules it out .

Soluble Endoglin (sEng) Endoglin is a co-receptor for transforming growth factor-beta (TGF-β), involved in vascular development. Its soluble form (sEng) acts as a decoy receptor, inhibiting TGF-β signaling, contributing to endothelial dysfunction, a key feature of preeclampsia. sEng levels are elevated in the maternal circulation prior to clinical onset and correlate with disease severity.

Osteoprotegerin (OPG) OPG, a member of the TNF receptor superfamily, is primarily involved in bone metabolism but also plays a role in vascular biology. Some studies have reported altered OPG levels in preeclampsia, potentially reflecting vascular damage or endothelial activation . Its role remains less defined, but it may complement other angiogenic markers in profiling disease status.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • IInclusion Criteria:
  • Pregnant women between 20 and 36 weeks of gestation
  • Age between 18 and 45 years
  • Attending the antenatal clinic at the study site

排除标准

  • Chronic hypertension
  • Renal disease
  • Diabetes mellitus
  • Multiple gestations
  • Autoimmune disorders

研究组 & 干预措施

Preeclampsia - No Antihypertensive Treatment

This group includes pregnant women diagnosed with preeclampsia. Blood samples are collected at the time of diagnosis before starting any antihypertensive treatment. All participants will receive standard clinical care after sample collection. Samples will be processed, aliquoted, and stored at -80°C for biomarker analysis (sFlt-1, PlGF, soluble endoglin, and osteoprotegerin).

Preeclampsia - With Antihypertensive Treatment

is group includes pregnant women diagnosed with preeclampsia who are receiving standard antihypertensive therapy as part of their clinical care. Blood samples (5 mL) will be collected for measurement of biomarkers (sFlt-1, PlGF, sEng, OPG). Samples will be processed, aliquoted, and stored at -80°C. Clinical parameters and treatment details will also be recorded for analysi

Healthy Pregnant Controls

his group includes healthy pregnant women without preeclampsia. Blood samples (5 mL) will be collected to serve as controls for biomarker analysis. Samples will be processed, aliquoted, and stored at -80°C. Participants will receive routine prenatal care.

结局指标

主要结局

Change in sFlt-1/PlGF ratio and soluble endoglin (sEng) levels in preeclamptic patients compared to healthy pregnant controls.

时间窗: From diagnosis until delivery (or until clinical follow-up after treatment initiation).

The primary outcome is to assess the difference in angiogenic and anti-angiogenic biomarker levels between preeclamptic patients and healthy controls. Samples will be collected at diagnosis (before any antihypertensive treatment) and analyzed using ELISA. Changes in these biomarkers with treatment will also be monitored to evaluate treatment response.

次要结局

  • Combined biomarker panel for early detection and monitoring of preeclampsia.(From diagnosis until delivery.)

研究者

发起方
Ammar Jassim Abed
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Ammar Jassim Abed

Master's Student (MSc Researcher), Principal Investigator

University of Thi-Qar

研究点 (1)

Loading locations...

相似试验